Back to Search Start Over

Desmoglein-2 as a cancer modulator: friend or foe?

Authors :
Myo Min KK
Ffrench CB
McClure BJ
Ortiz M
Dorward EL
Samuel MS
Ebert LM
Mahoney MG
Bonder CS
Source :
Frontiers in oncology [Front Oncol] 2023 Dec 22; Vol. 13, pp. 1327478. Date of Electronic Publication: 2023 Dec 22 (Print Publication: 2023).
Publication Year :
2023

Abstract

Desmoglein-2 (DSG2) is a calcium-binding single pass transmembrane glycoprotein and a member of the large cadherin family. Until recently, DSG2 was thought to only function as a cell adhesion protein embedded within desmosome junctions designed to enable cells to better tolerate mechanical stress. However, additional roles for DSG2 outside of desmosomes are continuing to emerge, particularly in cancer. Herein, we review the current literature on DSG2 in cancer and detail its impact on biological functions such as cell adhesion, proliferation, migration, invasion, intracellular signaling, extracellular vesicle release and vasculogenic mimicry. An increased understanding of the diverse repertoire of the biological functions of DSG2 holds promise to exploit this cell surface protein as a potential prognostic biomarker and/or target for better patient outcomes. This review explores the canonical and non-canonical functions of DSG2, as well as the context-dependent impacts of DSG2 in the realm of cancer.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Myo Min, Ffrench, McClure, Ortiz, Dorward, Samuel, Ebert, Mahoney and Bonder.)

Details

Language :
English
ISSN :
2234-943X
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
38188287
Full Text :
https://doi.org/10.3389/fonc.2023.1327478